EPZM Epizyme, Inc. Stock Quote

EPZM [NASD]

Index	-	P/E	-	EPS (ttm)	-2.52	Insider Own	1.20%	Shs Outstand	102.05M	Perf Week	5.33%
Market Cap	611.73M	Forward P/E	-	EPS next Y	-1.83	Insider Trans	4.09%	Shs Float	79.09M	Perf Month	12.35%
Income	-256.90M	PEG	-	EPS next Q	-0.49	Inst Own	97.80%	Short Float	12.40%	Perf Quarter	-33.29%
Sales	32.60M	P/S	18.76	EPS this Y	-19.10%	Inst Trans	-1.08%	Short Ratio	8.53	Perf Half Y	-36.19%
Book/sh	0.31	P/B	18.48	EPS next Y	15.70%	ROA	-63.70%	Target Price	-	Perf Year	-56.33%
Cash/sh	2.29	P/C	2.51	EPS next 5Y	38.00%	ROE	-216.20%	52W Range	4.72 - 14.30	Perf YTD	-47.24%
Dividend	-	P/FCF	-	EPS past 5Y	7.10%	ROI	-59.60%	52W High	-59.93%	Beta	1.19
Dividend %	-	Quick Ratio	6.60	Sales past 5Y	43.80%	Gross Margin	73.10%	52W Low	21.40%	ATR	0.26
Employees	304	Current Ratio	6.70	Sales Q/Q	420.00%	Oper. Margin	-	RSI (14)	53.73	Volatility	5.95% 5.11%
Optionable	Yes	Debt/Eq	7.34	EPS Q/Q	-9.10%	Profit Margin	-	Rel Volume	2.10	Prev Close	5.41
Shortable	Yes	LT Debt/Eq	7.34	Earnings	Aug 09 BMO	Payout	-	Avg Volume	1.15M	Price	5.73
Recom	2.10	SMA20	8.91%	SMA50	-5.53%	SMA200	-35.20%	Volume	2,419,310	Change	5.91%

May-07-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

$12 → $16

Apr-23-21

Resumed

Cowen

Outperform

$14

Mar-31-21

Initiated

Credit Suisse

Outperform

$13

Feb-25-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$14

Dec-21-20

Downgrade

Jefferies

Buy → Hold

$14

Apr-01-20

Downgrade

Oppenheimer

Outperform → Perform

Mar-04-20

Initiated

Barclays

Overweight

$33

Feb-25-20

Reiterated

H.C. Wainwright

Buy

$25 → $36

Jan-24-20

Downgrade

SVB Leerink

Outperform → Mkt Perform

Dec-06-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

May-30-19

Resumed

Citigroup

Buy

Jan-07-19

Upgrade

Leerink Partners

Mkt Perform → Outperform

Sep-07-18

Resumed

Morgan Stanley

Equal-Weight

Jul-03-18

Downgrade

Leerink Partners

Outperform → Mkt Perform

Jan-24-18

Resumed

Jefferies

Buy

$25

Jan-10-18

Initiated

Morgan Stanley

Overweight

$20

Nov-02-17

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$20 → $16

Sep-20-17

Initiated

Jefferies

Buy

$23

May-10-17

Resumed

RBC Capital Mkts

Outperform

$19 → $20

Apr-13-17

Initiated

Oppenheimer

Outperform

Sep-14-21 06:30AM	Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress Business Wire
Sep-08-21 11:30AM	Why Is Epizyme (EPZM) Up 3.8% Since Last Earnings Report? Zacks
Aug-20-21 08:00AM	Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-10-21 03:40PM	Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates Zacks -6.14%
07:16AM	Industry Analysts Just Made A Captivating Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts Simply Wall St.
Aug-09-21 06:30PM	Epizyme, inc (EPZM) Q2 2021 Earnings Call Transcript Motley Fool -9.43%
04:55PM	Why Epizyme Is Getting Crushed Today Motley Fool
08:45AM	Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:35AM	Epizyme Announces CEO Succession Business Wire
07:30AM	Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire
Aug-08-21 08:00PM	HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China GlobeNewswire
08:00PM	Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China Business Wire
Aug-03-21 04:01PM	Epizyme Announces Date of Second Quarter 2021 Financial Results Business Wire
Jul-27-21 06:48PM	Here is What Hedge Funds Think About Epizyme Inc (EPZM) Insider Monkey
03:03PM	Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-02-21 08:41AM	Why Epizyme Stock Is Falling This Week Motley Fool -5.91%
Jun-28-21 04:15AM	Epizyme, Inc. (NASDAQ:EPZM) Insiders Increased Their Holdings Simply Wall St.
Jun-16-21 06:30AM	Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients Business Wire
Jun-14-21 12:59PM	Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models Benzinga
May-25-21 06:30AM	Epizyme to Participate in Jefferies Virtual Healthcare Conference Business Wire
May-12-21 04:01PM	Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June Business Wire
May-07-21 05:30PM	Epizyme Inc (EPZM) Q1 2021 Earnings Call Transcript Motley Fool +21.73%
08:44AM	SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug MarketWatch
07:24AM	Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates Zacks
May-06-21 08:05AM	Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates Zacks -9.44%
06:30AM	Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results Business Wire
Apr-29-21 06:30AM	Epizyme Announces Date of First Quarter 2021 Financial Results Business Wire
Apr-01-21 12:13PM	2 Strong Buy Stocks Insiders Are Snapping Up TipRanks
Mar-25-21 11:30AM	Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound? Zacks
Mar-02-21 12:00PM	Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Companys Strategic Vision Call Business Wire
Feb-28-21 01:34AM	The Epizyme, Inc. (NASDAQ:EPZM) Analysts Have Been Trimming Their Sales Forecasts Simply Wall St.
Feb-25-21 10:03AM	Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2021 Benzinga -5.20%
Feb-24-21 06:30AM	Epizyme to Host Strategic Vision Call on March 2, 2021 Business Wire
Feb-23-21 08:00PM	Epizyme Inc (EPZM) Q4 2020 Earnings Call Transcript Motley Fool
10:31AM	CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
10:04AM	Return On Capital Employed Overview: Epizyme Benzinga
07:24AM	Epizyme: Q4 Earnings Insights Benzinga
06:15AM	Epizyme, Inc. to Host Earnings Call ACCESSWIRE
Feb-20-21 09:36AM	The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings Benzinga
Feb-16-21 06:30AM	Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences Business Wire
Jan-25-21 07:52AM	Is Epizyme (NASDAQ:EPZM) Weighed On By Its Debt Load? Simply Wall St.
Dec-18-20 02:43PM	Is EPZM A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-06-20 11:30AM	Epizyme (EPZM) Down 3.4% Since Last Earnings Report: Can It Rebound? Zacks
Nov-29-20 12:30PM	Billionaire Israel Englander Pours Money Into 2 Strong Buy Stocks TipRanks
Nov-16-20 05:16AM	Carl Goldfischer Is The Independent Director of Epizyme, Inc. (NASDAQ:EPZM) And Just Spent US$60k On Shares Simply Wall St.
Nov-15-20 11:16PM	Carl Goldfischer Is The Independent Director of Epizyme, Inc. (NASDAQ:EPZM) And Just Spent US$60k On Shares Simply Wall St.
Nov-13-20 12:56PM	Insider Buys Epizyme's Shares Benzinga
Nov-11-20 04:05PM	Epizyme to Participate in Jefferies Virtual London Healthcare Conference Business Wire
06:15AM	Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Slashed Next Year's Revenue Estimates By 20% Simply Wall St.
Nov-10-20 05:50AM	Earnings Update: Epizyme, Inc. (NASDAQ:EPZM) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St. +6.38%
Nov-09-20 10:16AM	Epizyme's (EPZM) Q3 Loss Narrower Than Expected, Sales Miss Zacks +10.74%
Nov-08-20 09:24AM	Epizyme, Inc. (NASDAQ:EPZM): Are Analysts Optimistic? Simply Wall St.
Nov-06-20 07:31PM	Epizyme Inc (EPZM) Q3 2020 Earnings Call Transcript Motley Fool -23.69%
07:53AM	Recap: Epizyme Q3 Earnings Benzinga
07:45AM	Epizyme (EPZM) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:30AM	Epizyme Reports Business Progress and Third Quarter 2020 Financial Results Business Wire
06:05AM	Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives Business Wire
06:00AM	Epizyme, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-20 06:30AM	Epizyme Announces Date of Third Quarter 2020 Financial Results Business Wire
Oct-28-20 12:33PM	Epizyme (EPZM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-07-20 03:29PM	Hedge Funds Are Getting Bullish On Epizyme Inc (EPZM) Insider Monkey
06:30AM	Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma Business Wire
Oct-02-20 09:21AM	Reflecting on Epizyme's (NASDAQ:EPZM) Share Price Returns Over The Last Three Years Simply Wall St.
Sep-08-20 06:30AM	Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Sep-03-20 11:31AM	Why Is Epizyme (EPZM) Up 0.6% Since Last Earnings Report? Zacks
Aug-18-20 01:05PM	Is Epizyme (NASDAQ:EPZM) A Risky Investment? Simply Wall St.
Aug-05-20 11:29AM	Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates Zacks +5.93%
Aug-04-20 05:00PM	Epizyme Inc (EPZM) Q2 2020 Earnings Call Transcript Motley Fool -14.41%
07:45AM	Epizyme (EPZM) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:18AM	Recap: Epizyme Q2 Earnings Benzinga
06:30AM	Epizyme Reports Business Progress and Second Quarter 2020 Financial Results Business Wire
Jul-28-20 06:30AM	Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
Jul-16-20 06:31PM	Were Hedge Funds Right About Epizyme Inc (EPZM)? Insider Monkey
Jun-28-20 09:31AM	Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares Simply Wall St.
Jun-20-20 07:57AM	Stock market gives up early gains to end lower as Apple plans to re-close stores and W.H.O. says coronavirus has entered new and dangerous phase MarketWatch
Jun-19-20 10:19AM	Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma Zacks -7.92%
10:02AM	Epizyme's shares fall after receiving new FDA approval for cancer drug MarketWatch
09:41AM	Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock? Zacks
Jun-18-20 01:31PM	Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK (tazemetostat) for Relapsed/Refractory Follicular Lymphoma Business Wire
08:34AM	The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions Benzinga
Jun-17-20 01:56PM	Hedge Funds Arent Done Buying Epizyme Inc (EPZM) Insider Monkey
Jun-16-20 07:09AM	2 Top Cancer Treatment Stocks to Buy in June Motley Fool
Jun-03-20 11:30AM	Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound? Zacks
May-26-20 12:55PM	Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT Thomson Reuters StreetEvents
May-14-20 09:22AM	Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions Zacks
May-13-20 05:12PM	Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program Business Wire
May-07-20 10:51AM	Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses Zacks
May-05-20 09:11AM	Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss Zacks +10.13%
May-04-20 07:00PM	Epizyme Inc (EPZM) Q1 2020 Earnings Call Transcript Motley Fool +5.33%
07:45AM	Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:04AM	Epizyme: Q1 Earnings Insights Benzinga
06:30AM	Epizyme Reports Business Progress and First Quarter 2020 Financial Results Business Wire
Apr-27-20 12:32PM	Earnings Preview: Epizyme (EPZM) Q1 Earnings Expected to Decline Zacks
06:30AM	Epizyme Announces Date of First Quarter 2020 Financial Results Business Wire
Apr-26-20 10:02AM	Is Epizyme, Inc.'s (NASDAQ:EPZM) CEO Overpaid Relative To Its Peers? Simply Wall St.
Apr-19-20 07:02AM	3 Top Biotech Stocks with FDA Approvals on the Horizon TipRanks
Apr-08-20 06:56PM	Is Epizyme Inc (EPZM) A Good Stock To Buy? Insider Monkey +11.83%
Mar-25-20 11:30AM	Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound? Zacks -6.01%
Mar-20-20 06:30AM	Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer Business Wire -6.55%
Mar-06-20 03:41AM	Edited Transcript of EPZM earnings conference call or presentation 24-Feb-20 1:30pm GMT Thomson Reuters StreetEvents

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kutok Jeffery	Chief Scientific Officer	Apr 05	Sale	8.80	2,029	17,855	54,028	Apr 07 06:15 AM
MOTT DAVID M	Director	Mar 26	Buy	7.97	34,486	274,817	150,900	Mar 29 04:30 PM
MOTT DAVID M	Director	Mar 25	Buy	7.98	28,231	225,283	116,414	Mar 29 04:30 PM
Bazemore Robert B	President & CEO	Mar 25	Sale	7.85	10,328	81,075	322,626	Mar 29 04:30 PM
Bazemore Robert B	President & CEO	Feb 04	Sale	11.21	3,890	43,607	331,977	Feb 05 04:41 PM
Beaulieu Joseph	Corporate Controller	Feb 04	Sale	11.21	227	2,545	13,431	Feb 05 04:40 PM
TOMBESI PAOLO	Chief Financial Officer	Feb 04	Sale	11.21	1,021	11,445	53,465	Feb 05 04:40 PM
Agarwal Shefali	Chief Medical Officer	Feb 04	Sale	11.21	969	10,862	104,341	Feb 05 04:41 PM
Ros Matthew	See Remarks	Feb 04	Sale	11.21	894	10,022	83,188	Feb 05 04:36 PM
Vakiener Victoria	Chief Commercial Officer	Feb 04	Sale	11.21	817	9,159	52,685	Feb 05 04:32 PM
Bazemore Robert B	President & CEO	Jan 25	Sale	11.41	6,069	69,247	248,367	Jan 27 08:44 PM
Ros Matthew	See Remarks	Jan 25	Sale	11.41	2,872	32,770	55,957	Jan 27 08:42 PM
Vakiener Victoria	Chief Commercial Officer	Jan 25	Sale	11.41	599	6,835	27,982	Jan 27 08:42 PM
Agarwal Shefali	Chief Medical Officer	Jan 25	Sale	11.41	2,872	32,770	75,727	Jan 27 08:38 PM
Agarwal Shefali	Chief Medical Officer	Dec 03	Sale	13.54	2,522	34,148	76,089	Dec 07 07:00 AM
GOLDFISCHER CARL	Director	Nov 11	Buy	12.07	5,000	60,350	5,000	Nov 13 07:05 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience